Artelo Biosciences Inc. (NASDAQ: ARTL) announced a strategic partnership with artificial intelligence company ScienceMachine to accelerate development of its fatty acid-binding protein 5 (FABP5) inhibitor platform.

The collaboration uses ScienceMachine's AI technology to analyze Artelo's internal FABP datasets and identify biological insights for FABP5 inhibitors, particularly ART26.12, the company's first FABP5 inhibitor in clinical studies. The partnership began in 2025 and has used machine learning to examine disease-model multi-omic data.

ScienceMachine identified potential proteins indicating FABP5 target engagement in ART26.12-treated healthy volunteers using data from Artelo's Phase 1 single ascending dose study. The collaboration also identified protein and lipid signatures correlated with ART26.12's analgesic effect.

"This collaboration expands our pipeline potential and enhances our R&D precision," said Andrew Yates, Senior Vice President and Chief Scientific Officer at Artelo. "We believe this partnership has the potential to accelerate the identification of novel mechanisms of action and clinical biomarkers."

Preliminary results from a psoriasis model are scheduled for publication later this year. The partnership revealed biological networks associated with disease severity and FABP signaling while providing mechanistic insight into novel targets.

Lorenzo Sani, CEO of ScienceMachine, said the collaboration demonstrates how AI agents can augment drug discovery and development by turning biological datasets into testable hypotheses for biomarker strategy and mechanism-of-action work.

Artelo describes itself as the first company to bring a selective FABP5 inhibitor into human studies targeting neuropathic pain. ART26.12 is under development as a non-opioid, non-steroidal analgesic for chemotherapy-induced peripheral neuropathy.

The information is based on a company press release statement.